4.7 Article

Nonlinear dimensionality reduction combining MR imaging with non-imaging information

Journal

MEDICAL IMAGE ANALYSIS
Volume 16, Issue 4, Pages 819-830

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.media.2011.12.003

Keywords

Manifold learning; Laplacian Eigenmaps; Classification; Metadata; Alzheimer's disease

Funding

  1. European Commission
  2. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  3. National Institute on Aging
  4. National Institute of Biomedical Imaging and Bioengineering
  5. Abbott
  6. AstraZeneca AB
  7. Bayer Schering Pharma AG
  8. Bristol-Myers Squibb
  9. Eisai Global Clinical Development
  10. Elan Corporation
  11. Genentech
  12. GE Healthcare
  13. GlaxoSmithKline
  14. Innogenetics
  15. Johnson and Johnson
  16. Eli Lilly and Co.
  17. Medpace, Inc.
  18. Merck and Co., Inc.
  19. Novartis AG
  20. Pfizer Inc.
  21. F. Hoffman-La Roche
  22. Schering-Plough
  23. Synarc, Inc.
  24. Alzheimer's Association
  25. Alzheimer's Drug Discovery Foundation
  26. NIH [P30 AG010129, K01 AG030514]
  27. Dana Foundation
  28. Medical Research Council [MC_U120061309, MR/K006355/1] Funding Source: researchfish
  29. MRC [MR/K006355/1, MC_U120061309] Funding Source: UKRI

Ask authors/readers for more resources

We propose a framework for the extraction of biomarkers from low-dimensional manifolds representing inter-subject brain variation. Manifold coordinates of each image capture information about structural shape and appearance and, when a phenotype exists, about the subject's clinical state. Our framework incorporates subject meta-information into the manifold learning step. Apart from gender and age, information such as genotype or a derived biomarker is often available in clinical studies and can inform the classification of a query subject. Such information, whether discrete or continuous, is used as an additional input to manifold learning, extending the Laplacian Eigenmap objective function and enriching a similarity measure derived from pairwise image similarities. The biomarkers identified with the proposed method are data-driven in contrast to a priori defined biomarkers derived from, e.g., manual or automated segmentations. They form a unified representation of both the imaging and non-imaging measurements, providing a natural use for data analysis and visualization. We test the method to classify subjects with Alzheimer's Disease (AD), mild cognitive impairment (MCI) and healthy controls enrolled in the ADNI study. Non-imaging metadata used are ApoE genotype, a risk factor associated with AD. and the CSF-concentration of A beta(1-42), an established biomarker for AD. In addition, we use hippocampal volume as a derived imaging-biomarker to enrich the learned manifold. Our classification results compare favorably to what has been reported in a recent meta-analysis using established neuroimaging methods on the same database. (C) 2011 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available